AI English summary of an SEC filing — figures as filed
Dexcom DXCMThe company said stockholders approved an increase of 3,400,000 shares in the shares reserved for issuance under the Amended and Restated 2015 Equity Incentive Plan on May 8, 2025.
Key points
AI summaryThe company said stockholders approved an increase of 3,400,000 shares in the shares reserved for issuance under the Amended and Restated 2015 Equity Incentive Plan on May 8, 2025.
Dexcom said stockholders approved an increase of 8,000,000 shares in the shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan on May 8, 2025.
The company said its board approved reducing the size of the board to 9 directors effective May 8, 2025, and that stockholders elected 9 director nominees at the annual meeting on the same day.
Dexcom said it had 392,107,501 shares of common stock outstanding and entitled to vote as of the record date of March 13, 2025. 346,192,494 shares were present in person or represented by proxy at the annual meeting on May 8, 2025, constituting a quorum.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Stockholders Approve Increase in Equity Incentive Plan Reserve
The company said stockholders approved an increase of 3,400,000 shares in the shares reserved for issuance under the Amended and Restated 2015 Equity Incentive Plan on May 8, 2025.
Source · Based on the filing body and exhibits
Stockholders Approve Increase in Employee Stock Purchase Plan Reserve
Dexcom said stockholders approved an increase of 8,000,000 shares in the shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan on May 8, 2025.
Source · Based on the filing body and exhibits
Board Size Reduced to 9 Directors
The company said its board approved reducing the size of the board to 9 directors effective May 8, 2025, and that stockholders elected 9 director nominees at the annual meeting on the same day.
Source · Based on the filing body and exhibits
Annual Meeting Voting Results
Dexcom said it had 392,107,501 shares of common stock outstanding and entitled to vote as of the record date of March 13, 2025. 346,192,494 shares were present in person or represented by proxy at the annual meeting on May 8, 2025, constituting a quorum.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…